XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has signed an agreement with Applied Pharmaceutical Innovation. A not-for-profit institution at the University of Alberta, Applied supports translational drug development for industry and innovators. XPhyto’s psychedelic pharmaceutical production agreement calls for the synthesis of pharmaceutical-grade psychedelic compounds and the development of the standard operating procedures required to obtain regulatory approval for the commercial production process. As part of its psychedelic pharmaceutical program, XPhyto needs industrial-scale production of standardized active pharmaceutical ingredients. This agreement is part of that strategic plan. Applied brings with it an interdisciplinary team of more than 30 pharmaceutical scientists, clinicians, regulatory, patent and market experts as well as access to translational science executed in a framework that supports commercial success. Applied also offers expertise in retention of IP and ownership of work product, focused and efficient project execution, and regulatory compliant operations. “In late 2020, XPhyto secured a development agreement for the industrial production of psilocybin with a leading German university,” said XPhyto CEO Hugh Rogers in the press release. “Now, with Applied Pharmaceutical Innovation, we will turn our minds to the industrial production of additional psychedelic compounds. The company plans to expand its psychedelic programs in 2021, including scalable production of pharmaceutical grade compounds, drug formulations, and clinical evaluation.”
To view the full article, visit https://ibn.fm/kxVNW
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
